Lecanemab for Early Alzheimer’s Disease: 48-Month Results for ApoE e4 Non-carriers or Heterozygotes from the Clarity AD Open-Label Extension
Froelich et al
Lecanemab for Early Alzheimer’s Disease: 48-Month Results for ApoE e4 Non-carriers or Heterozygotes from the Clarity AD Open-Label Extension
